A case of Stappia indica-induced relapsing peritonitis confirmed by 16S ribosomal RNA gene sequencing analysis in a patient undergoing continuous ambulatory peritoneal dialysis.
Peritoneal dialysis
Relapsing peritonitis
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
08
11
2020
accepted:
29
01
2021
pubmed:
17
2
2021
medline:
25
11
2021
entrez:
16
2
2021
Statut:
ppublish
Résumé
A 69-year-old woman with 26-year history of systemic lupus erythematosus and 4-year history of peritoneal dialysis was hospitalized for treatment of bacterial peritonitis. On admission, peritoneal dialysate was collected and subjected to bacterial culture. Cell count in the cloudy peritoneal dialysate was 4194/μL, and Gram-negative bacilli were detected. Vancomycin (1 g/day) and ceftazidime (1 g/day) were administered intraperitoneally, which resulted in rapid decrease in cell count in the peritoneal dialysate. However, on the 7th hospital day, peritonitis relapsed with abdominal pain and cloudy dialysate. 16S ribosomal RNA gene sequencing analysis identified Stappia indica sp. as the causative bacteria. Although treatment with 1 g/day meropenem for an additional 3 weeks was effective, bacterial peritonitis relapsed 7 days after its discontinuation. Because biofilm formation was suspected, the peritoneal catheter was removed, and she was transferred to maintenance hemodialysis. After removal of the peritoneal catheter, bacterial peritonitis never relapsed. Stappia indica was initially discovered in the deep seawater of the Indian Ocean. The bacterium is rod-shaped, Gram-negative, and oxidase- and catalase-positive. There have been no reports on the clinical effects of genus Stappia. Given the frequent relapse in the present case, Stappia indica sp. may easily form biofilms and are likely resistant to antibiotics. Timely peritoneal catheter removal may be required in some cases of bacterial peritonitis as in the present case. Further case reports are required to further elucidate the clinical effects of Stappia indica on humans.
Identifiants
pubmed: 33590472
doi: 10.1007/s13730-021-00579-w
pii: 10.1007/s13730-021-00579-w
pmc: PMC8271035
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
402-408Informations de copyright
© 2021. Japanese Society of Nephrology.
Références
Nephrol Dial Transplant. 2010 Apr;25(4):1213-7
pubmed: 19948873
Appl Environ Microbiol. 2007 Feb;73(4):1266-76
pubmed: 17142374
Perit Dial Int. 2016 9-10;36(5):481-508
pubmed: 27282851
J Am Soc Nephrol. 2012 Aug;23(8):1398-405
pubmed: 22626818
Saudi J Kidney Dis Transpl. 2019 May-Jun;30(3):738-740
pubmed: 31249244
J Nippon Med Sch. 2019;86(1):55-57
pubmed: 30918158
Int J Syst Evol Microbiol. 2013 Apr;63(Pt 4):1350-1354
pubmed: 22798655
Int J Syst Evol Microbiol. 2011 Mar 18;:1763
pubmed: 21421929
Perit Dial Int. 2005 May-Jun;25(3):274-84
pubmed: 15981776
Syst Appl Microbiol. 2005 Oct;28(8):672-8
pubmed: 16261856
CEN Case Rep. 2014 Nov;3(2):127-131
pubmed: 28509185
Int J Syst Evol Microbiol. 2006 Jan;56(Pt 1):75-9
pubmed: 16403869
Genom Data. 2016 Dec 15;11:73-74
pubmed: 28018855
Semin Nephrol. 2017 Jan;37(1):66-76
pubmed: 28153196
Front Microbiol. 2015 Dec 16;6:1410
pubmed: 26733958
Int J Syst Evol Microbiol. 2010 Apr;60(Pt 4):733-736
pubmed: 19656920